Special Issue "Perspectives on Kaposi's Sarcoma"
Deadline for manuscript submissions: 30 November 2021.
Kaposi’s sarcoma (KS) remains a tumor that in the majority of cases is associated with human herpes virus 8 (HHV8 or K-HSV) infection. KS can occur in immunocompetent subjects (the endemic part) and also in immunosuppressed patients (HIV—human immunodeficiency virus or post-transplant for instance).
In Patients Living With HIV (PLWHIV), the incidence has dramatically decreased since the advent of highly active antiretroviral therapy (HAART) and, consequently, thanks to the better control of HIV replication. Nevertheless, the relative risk in this population remains very high, with rates that are 60–80-fold higher compared with the general population, despite suppressed HIV viremia in patients with CD4 cells >500/mm3. Some case reports and recent series have mentioned that cutaneous and/or visceral KS could occur in PLWHIV on antiretroviral therapy, such as HAART, with suppressed HIV viremia and high CD4T cell counts without any efficiency of conventional therapies. The hope now and in the near future for both endemic KS and epidemic KS seems to be based upon new drugs, such as targeted therapies, or new immunotherapeutic agents that improve KS patients’ outcomes.
This Special Issue will focus on current data concerning the pathogenesis of KS, particularly driven by infection of endothelial cells with HHV8, and the potential impact of new therapeutic approaches beyond the conventional chemotherapy and interferon use.
Prof. Jean-Philippe Spano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Kaposi’s sarcoma
- new drugs
- targeted therapies